FREE SHIPPING ON ORDERS OVER $150

potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Balancing the benefits and risks

$28.60

Quantity
- +
Description

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to Metformin in subjects with type 2 diabetes

potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Balancing the benefits and risks

The numbers tell the story

potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Balancing the benefits and risks

doi:10.1186/s12929-017-0379-z 154

potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Balancing the benefits and risks

Also, the hypothalamus's GIP receptor signaling controls body weight and appetite [150]

potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Balancing the benefits and risks

GB: Conceptualization, Supervision, Writing original draft, Writing review & editing

potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Balancing the benefits and risks

You may also like

recommand products